P1. 15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

P1. 15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

Background: Afatinib, a second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is the recommended first-line treatment for patients with advanced non-small cell lung cancer harbouring sensitizing EGFR mutations. The role of afatinib after failure of first-genera...

Full description

Saved in:
Bibliographic Details
Main Authors: Chai, Chee Shee, Ho, G., Liam, Chong Kin, A, Binti Alip, Pang, Y.
Format: E-Article
Language:English
Published: Elsevier 2018
Subjects:
R Medicine (General)
RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Online Access:http://ir.unimas.my/id/eprint/22820/1/JTO%202nd%20afatinib.pdf
http://ir.unimas.my/id/eprint/22820/
https://www.jto.org/article/S1556-0864(18)31905-1/fulltext
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Malaysia Sarawak
Language: English

Internet

http://ir.unimas.my/id/eprint/22820/1/JTO%202nd%20afatinib.pdf
http://ir.unimas.my/id/eprint/22820/
https://www.jto.org/article/S1556-0864(18)31905-1/fulltext

Similar Items